Revumenib is a small molecule menin inhibitor for the treatment of relapsed/refractory leukemia with KMT2A translocation. Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in the majority of infant acute lymphoblastic...
- Mechanism
- Curator reviewed · 2 references
Revumenib is an inhibitor of menin, a scaffold protein. Menin interacts with both wild-type and rearranged KMT2A, playing a crucial role in leukemogenesis by activating leukemogenic transcription pathways that drive differentiation arrest and cell proliferation. Revumenib disrupts the interaction between menin and KMT2A, thereby downregulating leukemogenic transcriptional pathways, reversing leukemic differentiation arrest, and promoting maturation of leukemia cells.
- Primary indication
- Revumenib is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation or a nucleophosmin 1 (NPM1) mutationin patients ≥1 year of age.Curator reviewed · 4 structured indications
- Formula / weight
- C32H47FN6O4S · 630.82 g/mol (avg)
- First approval
- United States, 2024
- Also known as
- Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-
- Code names
- SNDX-50613 free base · SNDX-5613 free base
- Brand names
Resolves to
FRVSRBKUQZKTOW-YOCNBXQISA-NSMILESCCN(C(C)C)C(=O)C1=CC(F)=CC=C1OC1=CN=CN=C1N1CC2(C1)CCN(C[C@H]1CC[C@@H](CC1)NS(=O)(=O)CC)CC2What you can answer from here — as of September 13, 2026
Which drugs share a target with Revumenib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account